The Diagnostic Work-up of Cancer-associated Myositis

Overview

Journal Curr Opin Rheumatol

Specialty Rheumatology

Date 2018 Jul 3

PMID 29965856

Citations 18

Authors

Albert Selva-OCallaghan

Xavier Martinez-Gomez

Ernesto Trallero-Araguas

Iago Pinal-Fernandez

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Despite the well-recognized association between malignancy and myositis, definite data indicating the best strategy for diagnosing cancer in myositis patients is lacking. In this article, we review the data on cancer screening in patients with myositis, and propose an algorithm for this purpose based on recently published data.

Recent Findings: Evidence has recently emerged supporting blind screening in patients with certain myositis phenotypes. In addition to the clinical examination, imaging techniques such as PET/computed tomography scanning and whole-body MRI, and determination of the autoantibody profile beyond anti-TIF1γ antibody, the well known cancer biomarker in dermatomyositis, will help the clinician face this complex clinical situation. Molecules related to the checkpoint inhibitor pathway, specifically soluble programmed death 1, may also have a role in the diagnostic work-up of cancer in myositis. In the future, blood tests analysing circulating DNA will certainly help in detecting patients with cancer-associated myositis (CAM).

Summary: A step forward has been achieved in the pathway to establish optimal cancer screening for myositis patients. International consensus guidelines for an effective diagnostic work-up of CAM are in progress and will be of paramount importance to improving the outcome in these patients.

Citing Articles

[Muscle pain in myositis in a young female patient: what is behind this?].

Doblinger N, Doenz J, Tews H, Demirci C, Schmid S, Michels B Inn Med (Heidelb). 2024; 65(11):1150-1153.

PMID: 39120705 PMC: 11543706. DOI: 10.1007/s00108-024-01761-9.

Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.

van Erp M, Slaats F, Emmen J, Hamont D BMJ Case Rep. 2024; 17(1).

PMID: 38262717 PMC: 10826498. DOI: 10.1136/bcr-2022-253636.

Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies.

Ghirardello A, Gatto M, Franco C, Zanatta E, Padoan R, Ienna L Diagnostics (Basel). 2023; 13(19).

PMID: 37835823 PMC: 10572214. DOI: 10.3390/diagnostics13193080.

Coexistence of Multiple Myositis-Specific Antibodies in Patients with Idiopathic Inflammatory Myopathies.

Huang H, Lin W, Tsai W, Weng C, Weng M, Wu C J Clin Med. 2022; 11(23).

PMID: 36498547 PMC: 9739947. DOI: 10.3390/jcm11236972.

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.

Li X, Huang Y, Liu Y, Yan S, Li L, Cheng L Clin Rheumatol. 2022; 42(3):817-830.

PMID: 36357631 PMC: 9935732. DOI: 10.1007/s10067-022-06425-3.

References

Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y . Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017; 19(1):259. PMC: 5702134. DOI: 10.1186/s13075-017-1469-8. View

Greenberg S, Pinkus J, Amato A, Kristensen T, Dorfman D . Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016; 139(Pt 5):1348-60. DOI: 10.1093/brain/aww024. View

Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen J . Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018; 97(2):e9639. PMC: 5943873. DOI: 10.1097/MD.0000000000009639. View

Chen H, Peng Q, Yang H, Yin L, Shi J, Zhang Y . Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. J Rheumatol. 2018; 45(6):835-840. DOI: 10.3899/jrheum.170544. View

Kadoya M, Hida A, Maeda M, Taira K, Ikenaga C, Uchio N . Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016; 3(6):e290. PMC: 5056647. DOI: 10.1212/NXI.0000000000000290. View

Lundberg I, Tjarnlund A, Bottai M, Werth V, Pilkington C, de Visser M . 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017; 76(12):1955-1964. PMC: 5736307. DOI: 10.1136/annrheumdis-2017-211468. View

Pinal-Fernandez I, Parks C, Werner J, Albayda J, Paik J, Danoff S . Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care Res (Hoboken). 2016; 69(2):263-270. PMC: 5079847. DOI: 10.1002/acr.22920. View

Minami S, Nakanishi T, Tanaka T, Muro Y, Fujimoto N . A case of antisynthetase syndrome with elevated serum CA19-9 associated with interstitial lung disease. Eur J Dermatol. 2016; 27(1):78-80. DOI: 10.1684/ejd.2016.2890. View

Stubgen J . Inflammatory myopathies and lymphoma. J Neurol Sci. 2016; 369:377-389. DOI: 10.1016/j.jns.2016.08.060. View

10.

Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martinez M, Milisenda J . Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2017; 57(2):388-396. PMC: 5850766. DOI: 10.1093/rheumatology/kex413. View

11.

Huang Z, Gao B, Chen H, Yang M, Chen X, Yan R . An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis. PLoS One. 2017; 12(7):e0181069. PMC: 5513424. DOI: 10.1371/journal.pone.0181069. View

12.

Qiang J, Kim W, Baibergenova A, Alhusayen R . Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2016; 21(2):131-136. DOI: 10.1177/1203475416665601. View

13.

Olthoff A, Carstens P, Zhang S, von Fintel E, Friede T, Lotz J . Evaluation of dysphagia by novel real-time MRI. Neurology. 2016; 87(20):2132-2138. DOI: 10.1212/WNL.0000000000003337. View

14.

Dardis C, Antezana A, Tanji K, Maccabee P . Inclusion Body Myositis: A Case Presenting with Respiratory Failure and Autopsy Findings Leading to the Hypothesis of a Paraneoplastic Cause. Am J Case Rep. 2017; 18:700-706. PMC: 5490508. DOI: 10.12659/ajcr.903566. View

15.

Joseph C, Darrah E, Shah A, Skora A, Casciola-Rosen L, Wigley F . Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2013; 343(6167):152-7. PMC: 4038033. DOI: 10.1126/science.1246886. View

16.

Allenbach Y, Keraen J, Bouvier A, Jooste V, Champtiaux N, Hervier B . High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016; 139(Pt 8):2131-5. DOI: 10.1093/brain/aww054. View

17.

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L . Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken). 2017; 69(11):1771-1776. PMC: 5509530. DOI: 10.1002/acr.23188. View

18.

Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J . Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015; 10:61. PMC: 4440264. DOI: 10.1186/s13023-015-0277-y. View

19.

Venalis P, Selickaja S, Lundberg K, Rugiene R, Lundberg I . Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis. Arthritis Care Res (Hoboken). 2017; 70(4):648-651. DOI: 10.1002/acr.23325. View

20.

Hendren E, Vinik O, Faragalla H, Haq R . Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol. 2017; 24(5):e429-e433. PMC: 5659167. DOI: 10.3747/co.24.3696. View